JP2000502101A - ベンゾイミダゾール化合物の合成法 - Google Patents
ベンゾイミダゾール化合物の合成法Info
- Publication number
- JP2000502101A JP2000502101A JP9522697A JP52269797A JP2000502101A JP 2000502101 A JP2000502101 A JP 2000502101A JP 9522697 A JP9522697 A JP 9522697A JP 52269797 A JP52269797 A JP 52269797A JP 2000502101 A JP2000502101 A JP 2000502101A
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- methyl
- pyridinyl
- dimethyl
- sulfinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 238000010189 synthetic method Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 39
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000002904 solvent Substances 0.000 claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 claims abstract description 19
- 238000000746 purification Methods 0.000 claims abstract description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- -1 4-methoxy-3,5-dimethyl-2-pyridinyl Chemical group 0.000 claims description 10
- 239000000543 intermediate Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000003444 phase transfer catalyst Substances 0.000 claims description 4
- 239000006184 cosolvent Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical group [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 abstract description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 9
- PSEPRWKZZJWRCB-UHFFFAOYSA-N (4-methoxy-3,5-dimethylpyridin-2-yl)methanol Chemical compound COC1=C(C)C=NC(CO)=C1C PSEPRWKZZJWRCB-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000376 reactant Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 9
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 238000002955 isolation Methods 0.000 description 4
- 239000011736 potassium bicarbonate Substances 0.000 description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- UBOXGVDOUJQMTN-UHFFFAOYSA-N 1,1,2-trichloroethane Chemical compound ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- USSBDBZGEDUBHE-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate Chemical compound [Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O USSBDBZGEDUBHE-UHFFFAOYSA-L 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の反応工程 工程1: 工程2: 工程3:からなり、全体の反応順序に共通の一つの主要な溶媒系を使用し、操作中に形成 した中間体を単離することなく、順に連続的に反応工程を実施することを特徴と する、(4−メトキシ−3,5−ジメチル−2−ピリジニル)メチルアルオールか ら5−メトキシ−2−[[(4−メトキシ−3,5−ジメチル−2−ピリジニル)−メ チル]スルフィニル]−1H−ベンゾイミダゾールを製造するための方法。 2.溶媒系が主溶媒および場合により一つまたはそれを超える補助溶媒からなる ことを特徴とする請求項1に記載の方法。 3.主溶媒が塩化メチレンであるであることを特徴とする請求項2に記載の方法 。 4.主溶媒がトルエンであることを特徴とする請求項2に記載の方法。 5.補助溶媒がアルコールであることを特徴とする請求項2に記載の方法。 6.工程1を−5℃〜25℃の温度で実施することを特徴とする請求項1に記載の 方法。 7.相間移動触媒を用いて工程2を実施することを特徴とする請求項1に記載の 方法。 8.相間移動触媒がテトラブチルアンモニウムクロリドである請求項7に記載の 方法。 9.工程2を30〜60℃の温度で実施することを特徴とする請求項1に記載の方法 。 10.得られた5−メトキシ−2−[[(4−メトキシ−3,5−ジメチル−2−ピリジ ニル)−メチル]スルフィニル]−1H−ベンゾイミダゾールを精製工程でさらに 精製する前記請求項のいずれか一項に記載の方法。 11.精製工程には、一つまたは複数の有機溶媒からの結晶化が含まれることを特 徴とする請求項10に記載の方法。 12.精製工程には酸またはギ酸アルキルを添加してpHを下げることによってアル カリ水から沈殿させることが含まれることを特徴とする請求項10に記載の方法。 13.請求項1〜12に記載のいずれか一項の方法によって5−メトキシ−2−[[( 4−メトキシ−3,5−ジメチル−2−ピリジニル)−メチル]スルフィニル]−1H −ベンゾイミダゾールを製造することを特徴とする、5−メトキシ−2−[[(4 −メトキシ−3,5−ジメチル−2−ピリジニル)−メチル]スルフィニル]−1H− ベンゾイミダゾールおよび製薬上許容しうる担体または希釈剤からなる医薬製剤 。 14.請求項1〜12のいずれか一項に記載の方法によって製造した5−メトキシ− 2−[[(4−メトキシ−3,5−ジメチル−2−ピリジニル)−メチル]スルフィニル ]−1H−ベンゾイミダゾール。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9504503A SE521100C2 (sv) | 1995-12-15 | 1995-12-15 | Förfarande för framställning av en bensimidazolförening |
| SE9504503-5 | 1995-12-15 | ||
| PCT/SE1996/001603 WO1997022603A1 (en) | 1995-12-15 | 1996-12-05 | Method for the synthesis of a benzimidazole compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000502101A true JP2000502101A (ja) | 2000-02-22 |
| JP3523267B2 JP3523267B2 (ja) | 2004-04-26 |
Family
ID=20400614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52269797A Expired - Fee Related JP3523267B2 (ja) | 1995-12-15 | 1996-12-05 | ベンゾイミダゾール化合物の合成法 |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US5958955A (ja) |
| EP (1) | EP0868423B1 (ja) |
| JP (1) | JP3523267B2 (ja) |
| KR (1) | KR100433436B1 (ja) |
| CN (1) | CN1113879C (ja) |
| AR (1) | AR004834A1 (ja) |
| AT (1) | ATE205201T1 (ja) |
| AU (1) | AU704422B2 (ja) |
| CA (1) | CA2238864C (ja) |
| CO (1) | CO4750654A1 (ja) |
| CZ (1) | CZ288661B6 (ja) |
| DE (2) | DE868423T1 (ja) |
| DK (1) | DK0868423T3 (ja) |
| DZ (1) | DZ2137A1 (ja) |
| EE (1) | EE03768B1 (ja) |
| EG (1) | EG23859A (ja) |
| ES (1) | ES2125210T3 (ja) |
| HR (1) | HRP960581B1 (ja) |
| HU (1) | HUP9900110A3 (ja) |
| IL (1) | IL124856A (ja) |
| IS (1) | IS1891B (ja) |
| MA (1) | MA24026A1 (ja) |
| MX (1) | MX9804603A (ja) |
| MY (1) | MY115661A (ja) |
| NO (1) | NO314306B1 (ja) |
| NZ (1) | NZ324482A (ja) |
| PL (1) | PL186132B1 (ja) |
| PT (1) | PT868423E (ja) |
| RU (1) | RU2166502C2 (ja) |
| SE (1) | SE521100C2 (ja) |
| SI (1) | SI0868423T1 (ja) |
| SK (1) | SK282347B6 (ja) |
| TN (1) | TNSN96148A1 (ja) |
| TR (1) | TR199801070T2 (ja) |
| TW (1) | TW460474B (ja) |
| UA (1) | UA62921C2 (ja) |
| WO (1) | WO1997022603A1 (ja) |
| YU (1) | YU49420B (ja) |
| ZA (1) | ZA9610067B (ja) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006505567A (ja) * | 2002-10-18 | 2006-02-16 | アストラゼネカ・アクチエボラーグ | ベンゾイミダゾール化合物の合成方法 |
| JP2008524190A (ja) * | 2004-12-16 | 2008-07-10 | シプラ・リミテッド | パントプラゾールナトリウムの製造方法 |
| JP2010519284A (ja) * | 2007-02-21 | 2010-06-03 | シプラ・リミテッド | エソメプラゾールマグネシウム二水和物の調製方法 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521100C2 (sv) * | 1995-12-15 | 2003-09-30 | Astra Ab | Förfarande för framställning av en bensimidazolförening |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| SK283805B6 (sk) | 1996-09-09 | 2004-02-03 | Slovakofarma, A. S. | Spôsob prípravy omeprazolu |
| US6303787B1 (en) * | 1998-05-27 | 2001-10-16 | Natco Pharma Limited | Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates |
| SI20019A (sl) * | 1998-07-13 | 2000-02-29 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola |
| US6166213A (en) * | 1998-08-11 | 2000-12-26 | Merck & Co., Inc. | Omeprazole process and compositions thereof |
| IL142703A (en) | 1998-11-10 | 2006-04-10 | Astrazeneca Ab | Crystalline form of omeprazole |
| UA72748C2 (en) * | 1998-11-10 | 2005-04-15 | Astrazeneca Ab | A novel crystalline form of omeprazole |
| RU2247120C2 (ru) * | 1999-10-28 | 2005-02-27 | Грюненталь Гмбх | Способ получения противоязвенных терапевтических средств |
| DE19951960C2 (de) | 1999-10-28 | 2002-06-27 | Gruenenthal Gmbh | Verfahren zur Herstellung als Ulkustherapeutika geeigneter Benzimidazol-Derivate |
| US20040006111A1 (en) * | 2002-01-25 | 2004-01-08 | Kenneth Widder | Transmucosal delivery of proton pump inhibitors |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| CN100393712C (zh) * | 2006-01-23 | 2008-06-11 | 中国科学院成都有机化学有限公司 | 苯并咪唑型质子泵抑止剂及其前体的改进制备和分离纯化方法 |
| WO2007122686A1 (ja) * | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
| CN101492459B (zh) * | 2008-01-25 | 2011-04-27 | 山东轩竹医药科技有限公司 | 含烷氧乙酰基二氢异噁唑并吡啶化合物 |
| CN101497603B (zh) * | 2008-01-30 | 2012-11-07 | 山东轩竹医药科技有限公司 | 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物 |
| CN103664885A (zh) * | 2013-12-12 | 2014-03-26 | 武汉工程大学 | 苯并咪唑型质子泵抑制剂中间体的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US461997A (en) * | 1891-10-27 | Sand-pump or other pipes | ||
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| US4619997A (en) * | 1984-09-06 | 1986-10-28 | The Upjohn Company | Substituted 2-pyridylmethylthio and sulfinyl-benzimidazoles as gastric antisecretory agents |
| IL76839A (en) * | 1984-10-31 | 1988-08-31 | Byk Gulden Lomberg Chem Fab | Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
| SE9002043D0 (sv) * | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
| WO1993006097A1 (en) * | 1991-09-20 | 1993-04-01 | Merck & Co., Inc. | Novel process for the preparation of anti-ulcer agents |
| SE521100C2 (sv) * | 1995-12-15 | 2003-09-30 | Astra Ab | Förfarande för framställning av en bensimidazolförening |
-
1995
- 1995-12-15 SE SE9504503A patent/SE521100C2/sv not_active IP Right Cessation
-
1996
- 1996-05-12 UA UA98052782A patent/UA62921C2/uk unknown
- 1996-11-29 ZA ZA9610067A patent/ZA9610067B/xx unknown
- 1996-12-02 AR ARP960105459A patent/AR004834A1/es active IP Right Grant
- 1996-12-02 TN TNTNSN96148A patent/TNSN96148A1/fr unknown
- 1996-12-03 TW TW085114881A patent/TW460474B/zh not_active IP Right Cessation
- 1996-12-04 YU YU64296A patent/YU49420B/sh unknown
- 1996-12-04 MA MA24415A patent/MA24026A1/fr unknown
- 1996-12-04 DZ DZ960182A patent/DZ2137A1/fr active
- 1996-12-05 DE DE0868423T patent/DE868423T1/de active Pending
- 1996-12-05 DK DK96942702T patent/DK0868423T3/da active
- 1996-12-05 TR TR1998/01070T patent/TR199801070T2/xx unknown
- 1996-12-05 US US08/776,222 patent/US5958955A/en not_active Expired - Lifetime
- 1996-12-05 CA CA002238864A patent/CA2238864C/en not_active Expired - Fee Related
- 1996-12-05 EP EP96942702A patent/EP0868423B1/en not_active Expired - Lifetime
- 1996-12-05 KR KR10-1998-0704454A patent/KR100433436B1/ko not_active Expired - Fee Related
- 1996-12-05 ES ES96942702T patent/ES2125210T3/es not_active Expired - Lifetime
- 1996-12-05 JP JP52269797A patent/JP3523267B2/ja not_active Expired - Fee Related
- 1996-12-05 IL IL12485696A patent/IL124856A/en not_active IP Right Cessation
- 1996-12-05 NZ NZ324482A patent/NZ324482A/xx unknown
- 1996-12-05 EE EE9800183A patent/EE03768B1/xx not_active IP Right Cessation
- 1996-12-05 WO PCT/SE1996/001603 patent/WO1997022603A1/en not_active Ceased
- 1996-12-05 SI SI9630367T patent/SI0868423T1/xx unknown
- 1996-12-05 AU AU11550/97A patent/AU704422B2/en not_active Ceased
- 1996-12-05 PL PL96327334A patent/PL186132B1/pl not_active IP Right Cessation
- 1996-12-05 CN CN96199057A patent/CN1113879C/zh not_active Expired - Fee Related
- 1996-12-05 SK SK768-98A patent/SK282347B6/sk not_active IP Right Cessation
- 1996-12-05 CZ CZ19981685A patent/CZ288661B6/cs not_active IP Right Cessation
- 1996-12-05 PT PT96942702T patent/PT868423E/pt unknown
- 1996-12-05 DE DE69615052T patent/DE69615052T2/de not_active Expired - Fee Related
- 1996-12-05 RU RU98110659/04A patent/RU2166502C2/ru not_active IP Right Cessation
- 1996-12-05 HU HU9900110A patent/HUP9900110A3/hu unknown
- 1996-12-05 AT AT96942702T patent/ATE205201T1/de not_active IP Right Cessation
- 1996-12-09 HR HR960581A patent/HRP960581B1/xx not_active IP Right Cessation
- 1996-12-11 CO CO96065025A patent/CO4750654A1/es unknown
- 1996-12-13 MY MYPI96005252A patent/MY115661A/en unknown
- 1996-12-14 EG EG112296A patent/EG23859A/xx active
-
1998
- 1998-05-22 IS IS4750A patent/IS1891B/is unknown
- 1998-06-08 NO NO19982624A patent/NO314306B1/no not_active IP Right Cessation
- 1998-06-09 MX MX9804603A patent/MX9804603A/es not_active IP Right Cessation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006505567A (ja) * | 2002-10-18 | 2006-02-16 | アストラゼネカ・アクチエボラーグ | ベンゾイミダゾール化合物の合成方法 |
| JP2008524190A (ja) * | 2004-12-16 | 2008-07-10 | シプラ・リミテッド | パントプラゾールナトリウムの製造方法 |
| US8691995B2 (en) | 2004-12-16 | 2014-04-08 | Cipla Limited | Process |
| JP2010519284A (ja) * | 2007-02-21 | 2010-06-03 | シプラ・リミテッド | エソメプラゾールマグネシウム二水和物の調製方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000502101A (ja) | ベンゾイミダゾール化合物の合成法 | |
| CN113563304B (zh) | 瑞卢戈利中间体及其制备方法 | |
| JP2018008985A (ja) | (5−フルオロ−2−メチル−3−キノリン−2−イルメチル−インドール−1−イル)−酢酸エステルの製造のための方法 | |
| JP2001500877A (ja) | オランザピンの製造方法および中間体 | |
| JP4551221B2 (ja) | ベンゾイミダゾール化合物の合成方法 | |
| JP2003531144A (ja) | [[(ピリジル置換)メチル]チオ]ベンズイミダゾールの誘導体を得る方法 | |
| JP2008509211A (ja) | 塩酸イリノテカン三水和物の改良された製造方法 | |
| JP2001512722A (ja) | L−アスコルビン酸の製造方法 | |
| US5811556A (en) | Preparation of mibefradil via a naphthalenylacetic acid | |
| JP2001515496A (ja) | 5−アミノメチル−クロロピリジン類の製造方法 | |
| WO2005037823A1 (en) | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazole-1-yl)methyl]-4h-carbazol-4-one or its salt | |
| JP2002540101A (ja) | プロピオン酸3−アミノ−3−アリールの合成 | |
| HK1010539B (en) | Method for the synthesis of a benzimidazole compound | |
| JP3230723B2 (ja) | 2−(フルフリルチオ)酢酸誘導体の製造方法 | |
| JP2002528546A (ja) | 2−(r)−(1−(r)−(3,5−ビス(トリフルオロメチル)フェニル)エトキシ−4−((5−ジメチルアミノメチル)−1,2,3−トリアゾル−4−イル)メチル)−3−(s)−(4−フルオロフェニル)モルホリン化合物の製造方法 | |
| JP2853929B2 (ja) | 2−クロロ−4,5−ジフルオロ−3−メトキシ安息香酸の製造方法 | |
| JP2009501146A (ja) | ベンズイミダゾール化合物の調製方法 | |
| JP2003518133A (ja) | 9−デオキソ−9(z)−ヒドロキシイミノエリスロマイシンaを製造、単離する方法 | |
| JPH051053A (ja) | 6−(3−ジメチルアミノプロピオニル)フオルスコリンの新規製造法 | |
| CN121405634A (zh) | 一种2-氰基-5-(对甲苯基)-1h-咪唑的合成方法 | |
| JPWO1998051653A1 (ja) | 2−ブロモ−5−メトキシベンジルブロミドの製造法 | |
| JP2002518376A (ja) | ホルミルイミダゾールの製造方法 | |
| WO2011136510A2 (ko) | 로자탄 대사체 이엑스피-3174 이수화물의 신규한 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040113 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040206 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080220 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090220 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100220 Year of fee payment: 6 |
|
| LAPS | Cancellation because of no payment of annual fees |